The GLP-1 Side Effect Nobody's Talking About (And What To Do Instead) with Kyal Van Der Leest

Why It Matters

Understanding GLP‑1 side effects is crucial for safe, sustainable weight loss and prevents unintended toxin redistribution that can affect metabolic health and organ function.

Key Takeaways

• GLP‑1 agonists accelerate fat loss but may cause gut issues
• High doses slow gastric motility, risking SIBO and bloating
• Rapid fat loss releases stored toxins, burdening liver and brain
• Microdosing GLP‑1s reduces side effects, improves tolerance
• Supplementing NAC, glycine, glutathione supports detox during weight loss

Pulse Analysis

The surge of GLP‑1 receptor agonists—Ozempic, Wegovy, and the newer dual‑agonist tirzepatide—has reshaped the weight‑loss market, promising double‑digit percent reductions in body weight within months. Their primary action, mimicking the incretin hormone GLP‑1, slows gastric emptying, curbs appetite, and enhances insulin sensitivity. However, clinicians increasingly observe that the standard high‑dose protocols, while effective for rapid results, also suppress gut motility to the point of fostering small‑intestinal bacterial overgrowth (SIBO) and increased intestinal permeability. These gastrointestinal disturbances can erode patient adherence and generate downstream health costs.

Beyond the gut, rapid adipose depletion releases lipophilic toxins that have accumulated in fat cells over years—heavy metals, persistent organic pollutants, and mold‑derived mycotoxins. When the liver’s phase‑I and phase‑II pathways are inundated, excess toxins may circulate to vulnerable tissues such as the brain, breast, and gastrointestinal lining, manifesting as ‘Ozempic face,’ cognitive fog, or inflammatory flare‑ups. This detox burden underscores a hidden risk of aggressive GLP‑1 therapy, prompting a shift toward integrated protocols that pair pharmacologic appetite control with targeted antioxidant and binding agents.

Micro‑dosing offers a pragmatic compromise: lower weekly or bi‑weekly GLP‑1 doses maintain appetite suppression while preserving enough gastric motility to avoid SIBO and reduce toxin mobilization. Practitioners like Dr. Tina Moore and Kyal Van Der Leest recommend adjunctive supplementation—N‑acetylcysteine, glycine, reduced glutathione, and clinically validated binders—to bolster hepatic detoxification and protect cellular membranes. For manufacturers and insurers, this approach could lower adverse‑event rates, improve long‑term adherence, and expand the therapeutic window of GLP‑1 products, ultimately driving sustainable market growth.

Original Description

GLP-1s like Ozempic and tirzepatide will make you lose weight. That part's not up for debate. But what happens inside your body when you lose fat fast — that's the conversation nobody's having.

Watch the full episode at https://youtu.be/XFte5B2VzWI

In this clip from Better with Dr. Stephanie, nutritionist and peptide formulator Kyal Van Der Leest breaks down the three types of GLP-1 agonists (single, dual, and triple), why mainstream dosing is often too high, and why he believes microdosing — as championed by Dr. Tina Moore — is the smarter approach. He explains how slowed gastric motility from higher doses can lead to bacterial overgrowth (SIBO), leaky gut, bloating, and digestive dysfunction.

But here's the part that might change how you think about rapid fat loss entirely: your fat is a storage organ for toxins. When you lose weight fast, you liberate heavy metals, endocrine disruptors, and other stored toxins that your liver may not be able to process quickly enough. Where do they go? Your brain. Your breast tissue. Your gut. Kyal shares his own experience of getting "Ozempic face" — not from Ozempic, but from detoxifying mold — and why NAC, glycine, glutathione, and binders are essential for anyone on a weight loss journey.

Two truths can be true: GLP-1s can be a useful tool, AND you need to do the foundational work alongside them.